A firm base for drug development

Bart De Strooper () and Gerhard König ()
Additional contact information
Bart De Strooper: Flanders Interuniversitary Institute for Biotechnology and K. U. Leuven
Gerhard König: Bayer AG, Pharma Research CNS

Nature, 1999, vol. 402, issue 6761, 471-472

Abstract: Alzheimer's disease is a progressive dementia in which massive protein deposits accumulate as either amyloid plaques or neurofibrillary tangles. The plaques are composed of a peptide called Aβ, which is liberated from its precursor, the amyloid precursor protein, by cleavage at two sites. The enzyme that cleaves at one of these sites, the β site, has now been identified, and it is likely to be a good target for drugs.

Date: 1999
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/44973 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:402:y:1999:i:6761:d:10.1038_44973

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/44973

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().